Abstract
Treatment-related Myelodysplastic Syndrome (t-MDS) is well known and serious complication of cancer treatment. However, MDS cases caused by therapy of common nonmalignant diseases are unusual and represent diagnosic and therapeutic challenge. We experienced a case of secondary MDS, possibly induced by trimetazidine dihydrochloride, which was spontaneously resolved by discontinuance of the drug. The main purpose of this report is to point at the importance of continuous and careful monitoring of pharmacovigilance data of different medications and their possible “relation” with some diseases or pathological conditions which are, in fact, adverse drug event.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
